Sera Prognostics (SERA) Expected to Announce Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $0.10 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Performance

Shares of NASDAQ SERA opened at $3.75 on Wednesday. The company has a market capitalization of $141.26 million, a P/E ratio of -4.41 and a beta of 0.97. Sera Prognostics has a 52-week low of $1.37 and a 52-week high of $9.13. The company’s 50 day moving average price is $3.14 and its 200-day moving average price is $2.71.

Analyst Ratings Changes

Several analysts have recently weighed in on SERA shares. Wall Street Zen upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 21,158 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total transaction of $66,647.70. Following the completion of the sale, the chief executive officer owned 811,136 shares in the company, valued at approximately $2,555,078.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 50,631 shares of company stock worth $153,604. Insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors boosted its holdings in Sera Prognostics by 20.0% during the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock worth $1,668,000 after acquiring an additional 100,366 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Sera Prognostics by 73.9% during the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after acquiring an additional 42,500 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Sera Prognostics during the 2nd quarter worth $92,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.